Date: 2011-07-14
Type of information: Development agreement
Compound: diagnostic product for penicillin allergy
Company: ALK (Denmark) AllerQuest (USA)
Therapeutic area: Allergic diseases - Immunological diseases
Type agreement: development
commercialisation
distribution
Action mechanism:
Disease:
Details: ALK and AllerQuest have entered into an agreement to develop and market a new diagnostic product for penicillin allergy. The new product – Minor Determinant Mixture (MDM) – currently being developed by AllerQuest will complement PRE-PEN® and provide for a complete and unique penicillin allergy diagnosis. Currently, PRE-PEN® is used in the USA in combination with other diagnostic products to ensure a complete test of penicillin allergy patients. The availability of MDM is expected to improve and to enhance diagnosis of penicillin allergy significantly and simplify the testing procedure with an easy to use uni-dosed kit for all kinds of clinics and hospitals. At present, ALK distributes PRE-PEN® in the USA. PRE-PEN® is developed by the US based company AllerQuest. Currently, PRE-PEN® is not registered and marketed in Europe. The combination of PRE-PEN® and the new diagnostic product (MDM) will have global market potential. As with PRE-PEN®, ALK will become exclusive distributor with global rights.
In total, ALK will pay up to $3.45 million for the exclusive distribution rights to MDM as well as the extension of the exclusive distribution rights of PRE-PEN®. Payments will be made in several instalments linked to the successful development and market launch of MDM. The clinical development programme is expected to be concluded in 2012 after which a registration application will be submitted to the FDA.
Financial terms: In total, ALK will pay up to $3.45 million for the exclusive distribution rights to MDM as well as the extension of the exclusive distribution rights of PRE-PEN®. Payments will be made in several instalments linked to the successful development and market launch of MDM.
Latest news:
